← Back to headlines
Ironwood Pharmaceuticals Reiterates 2026 LINZESS Guidance
Ironwood Pharmaceuticals has reaffirmed its financial guidance for LINZESS in 2026, projecting net sales between $1.125 billion and $1.175 billion, as the STARS-2 trial initiation approaches.
8 May, 00:22 — 8 May, 00:22
Sources
Showing 1 of 1 sources
